XML 174 R128.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details) - EUR (€)
€ in Millions
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Level 1      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value € 6,737 € 10,765 € 6,449
Total financial liabilities measured at fair value 0 0 0
Level 1 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 470 387 396
Level 1 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 346 329 447
Level 1 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 572 512 549
Level 1 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 5,349 9,537 5,057
Level 2      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 201 206 298
Total financial liabilities measured at fair value 291 326 85
Level 2 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 164 232 6
Level 2 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 127 94 79
Level 2 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 3
Level 2 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 201 206 295
Level 2 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 964 967 883
Total financial liabilities measured at fair value 709 779 714
Level 3 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 26 59
Level 3 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 127 204 269
Level 3 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 441 380 354
Level 3 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 137 165 0
Level 3 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 4 4 32
Level 3 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 3 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 3 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 618 549 427
Level 3 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 132 115 78
Level 3 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 214 303 378
Level 3 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value € 0 € 0 € 0